Bonner’s “4th and Final Prediction”—First 3 came true, will this too?
One of America’s most successful entrepreneurs goes public with ”4th and Final Prediction.” His first three all came true—will this one too?
Click here for details.
Zoran Zdraveski net worth and biography

Zoran Zdraveski Biography and Net Worth

Insider of TScan Therapeutics
Dr. Zoran Zdraveski is a Chief Legal Officer at TScan Therapeutics, Inc. Dr. Zdraveski was previously employed as a Secretary & Chief Legal Officer by Magenta Therapeutics, Inc. and a Vice President & Associate General Counsel by Epizyme, Inc. He received his undergraduate degree from Southern Methodist University, a graduate degree from Suffolk University Law School and a doctorate degree from Massachusetts Institute of Technology.

How old is Zoran Zdraveski?

Dr. Zdraveski is currently 52 years old. There are 2 older executives and no younger executives at TScan Therapeutics. The oldest executive at TScan Therapeutics is Mr. David P. Southwell, Pres, CEO & Director, who is 61 years old. Learn More on Zoran Zdraveski's age.

How do I contact Zoran Zdraveski?

The corporate mailing address for Dr. Zdraveski and other TScan Therapeutics executives is 830 WINTER STREET, WALTHAM MA, 02451. TScan Therapeutics can also be reached via phone at 857-399-9500 and via email at [email protected] Learn More on Zoran Zdraveski's contact information.

Has Zoran Zdraveski been buying or selling shares of TScan Therapeutics?

Zoran Zdraveski has not been actively trading shares of TScan Therapeutics within the last three months. Most recently, on Thursday, September 23rd, Zoran Zdraveski bought 4,716 shares of TScan Therapeutics stock. The stock was acquired at an average cost of $7.48 per share, with a total value of $35,275.68. Learn More on Zoran Zdraveski's trading history.

Who are TScan Therapeutics' active insiders?

TScan Therapeutics' insider roster includes Gavin MacBeath (Insider), Brian Silver (CFO), and Zoran Zdraveski (Insider). Learn More on TScan Therapeutics' active insiders.

Are insiders buying or selling shares of TScan Therapeutics?

In the last year, TScan Therapeutics insiders bought shares 2 times. They purchased a total of 40,000 shares worth more than $140,750.00. The most recent insider tranaction occured on May, 18th when CEO David P Southwell bought 25,000 shares worth more than $89,750.00. Insiders at TScan Therapeutics own 5.3 % of the company. Learn More about insider trades at TScan Therapeutics.

Information on this page was last updated on 5/18/2022.

Zoran Zdraveski Insider Trading History at TScan Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/23/2021Buy4,716$7.48$35,275.68View SEC Filing Icon  
See Full Table

Zoran Zdraveski Buying and Selling Activity at TScan Therapeutics

This chart shows Zoran Zdraveski's buying and selling at TScan Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TScan Therapeutics Company Overview

TScan Therapeutics logo
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $2.88
Low: $2.62
High: $2.88

50 Day Range

MA: $3.32
Low: $2.62
High: $4.39

2 Week Range

Now: $2.88
Low: $1.60
High: $9.35

Volume

16,000 shs

Average Volume

56,906 shs

Market Capitalization

$69.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13
Bonner’s “4th and Final Prediction”—First 3 came true, will this too?
One of America’s most successful entrepreneurs goes public with ”4th and Final Prediction.” His first three all came true—will this one too?
Click here for details.